**Core Concept**
Fatty liver, also known as hepatic steatosis, is a condition characterized by the accumulation of excess fat in liver cells. Various medications can contribute to the development of fatty liver by inducing liver damage, impairing lipid metabolism, or promoting insulin resistance.

**Why the Correct Answer is Right**
Chlorpropamide is a first-generation sulfonylurea used in the treatment of type 2 diabetes mellitus. It does not have a well-established association with the development of fatty liver. In contrast, the other options have been linked to liver damage or metabolic alterations that can contribute to the development of fatty liver. Amiodarone, an antiarrhythmic medication, is known to cause liver damage and has been associated with steatohepatitis. Zidovudine, an antiretroviral medication, can cause mitochondrial toxicity, leading to liver damage and fatty liver. Sodium valproate, an antiepileptic medication, can cause liver damage and has been associated with the development of fatty liver.

**Why Each Wrong Option is Incorrect**
**Option A:** Amiodarone can cause liver damage and steatohepatitis, making it a correct association with fatty liver.
**Option B:** Zidovudine can cause mitochondrial toxicity, leading to liver damage and fatty liver, making it a correct association.
**Option C:** Sodium valproate can cause liver damage and has been associated with the development of fatty liver, making it a correct association.

**Clinical Pearl / High-Yield Fact**
It's essential to recognize the potential for medications to contribute to the development of fatty liver, particularly in patients with pre-existing risk factors such as obesity, diabetes, or alcohol use disorder. A thorough medical history and regular monitoring of liver function tests can help identify patients at risk for fatty liver.

**✓ Correct Answer: D. Chlorpropamide. Chlorpropamide is not typically associated with fatty liver.**